文献速递心力衰竭与心肌病

动态血流动力学监测在真实世界临床实践中减少心力衰竭住院

Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice.
PubMed 文献 · J Am Coll Cardiol · 2017-03-19

基于美国医保索赔数据的回顾性队列研究显示,1,114例植入肺动脉压力传感器的患者,植入后6个月心衰住院率低于植入前6个月(HR 0.55,95%CI 0.49-0.61,p<0.001),且6个月心衰相关总费用每人降低7,433美元。在480例有完整12个月数据的患者中,住院率降低持续至1年(HR 0.66,95%CI 0.57-0.76,p<0.001)。

要点

  • 植入后6个月心衰住院风险低于植入前6个月(HR 0.55,95%CI 0.49-0.61,p<0.001)。
  • 植入后6个月心衰相关总费用每人降低7,433美元(IQR 7,000-7,884)。
  • 480例有完整12个月数据的患者中,住院率降低持续至1年(HR 0.66,95%CI 0.57-0.76,p<0.001)。

核心结论

  • 在临床实践中使用动态血流动力学监测与较低的心衰住院率和心衰相关总费用相关,获益持续至1年,支持该方法的真实世界有效性。

研究设计与样本

  • 回顾性队列研究,使用美国医保索赔数据,纳入2014年6月1日至2015年12月31日期间接受肺动脉压力传感器植入的患者1,114例。
  • 比较植入前后预设时间段内的心衰住院率,采用Andersen-Gill扩展的Cox比例风险模型并考虑死亡、心室辅助装置植入或心脏移植的竞争风险。
  • 比较相同时间段的心衰相关总费用。

主要发现

  • 1,114例患者中,植入前6个月发生1,020次心衰住院,植入后6个月发生381次心衰住院、139例死亡和17例心室辅助装置植入和/或移植(HR 0.55,95%CI 0.49-0.61,p<0.001)。
  • 较低的心衰住院率与6个月心衰相关总费用每人降低7,433美元相关(IQR 7,000-7,884),在仅限6个月存活者的分析中结果稳健。
  • 480例有植入前后12个月完整数据的患者中,心衰住院和费用也出现类似降低(HR 0.66,95%CI 0.57-0.76,p<0.001)。

关键数值与推荐

  • 植入后6个月 vs 植入前6个月心衰住院:HR 0.55(95%CI 0.49-0.61,p<0.001)。
  • 植入后6个月 vs 植入前6个月心衰相关总费用:每人降低7,433美元(IQR 7,000-7,884)。
  • 480例有完整12个月数据的患者中,植入后12个月 vs 植入前12个月心衰住院:HR 0.66(95%CI 0.57-0.76,p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New York Heart Association [NYHA] Functional Class III Heart Failure Patients) trial, heart failure hospitalization (HFH) rates were lower in patients managed with guidance from an implantable pulmonary artery pressure sensor compared with usual care. OBJECTIVES: This study examined the effectiveness of ambulatory hemodynamic monitoring in reducing HFH outside of the clinical trial setting. METHODS: We conducted a retrospective cohort study using U.S. Medicare claims data from patients undergoing pulmonary artery pressure sensor implantation between June 1, 2014, and December 31, 2015. Rates of HFH during pre-defined periods before and after implantation were compared using the Andersen-Gill extension to the Cox proportional hazards model while accounting for the competing risk of death, ventricular assist device implantation, or cardiac transplantation. Comprehensive heart failure (HF)-related costs were compared over the same periods. RESULTS: Among 1,114 patients receiving implants, there were 1,020 HFHs in the 6 months before, compared with 381 HFHs, 139 deaths, and 17 ventricular assist device implantations and/or transplants in the 6 months after implantation (hazard ratio [HR]: 0.55; 95% confidence interval [CI]: 0.49 to 0.61; p < 0.001). This lower rate of HFH was associated with a 6-month comprehensive HF cost reduction of $7,433 per patient (IQR: $7,000 to $7,884), and was robust in analyses restricted to 6-month survivors. Similar reductions in HFH and costs were noted in the subset of 480 patients with complete data available for 12 months before and after implantation (HR: 0.66; 95% CI: 0.57 to 0.76; p < 0.001). CONCLUSIONS: As in clinical trials, use of ambulatory hemodynamic monitoring in clinical practice is associated with lower HFH and comprehensive HF costs. These benefits are sustained to 1 year and support the "real-world" effectiveness of this approach to HF management.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice. J Am Coll Cardiol. 2017. PMID: 28330751. doi:10.1016/j.jacc.2017.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。